Treatment of Fat deposition in liver by a Unani Formulation.

Effect of Murabba-e-Zanjabeel in Non-Alcoholic Fatty Liver Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011531

Enrollment

Registered

2018-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Non-Alcoholic fatty Liver Disease

Interventions

Intervention1: Murabba-e-Zanjabeel: 5 grams, twice daily, orally for 45 days Control Intervention1: Wheat Flour capsules: 1 Capsule, Twice Daily, Orally for 45 days

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender 2. Age group of 18-60 years 3. Diagnosed cases of fatty liver (Grade I and Grade II) by ultrasonogram 4. Patients with/ without clinical signs and symptoms like Anorexia, Nausea, Dyspepsia, Fatigue, Dull ache/ Heaviness in right hypochondriac region and Hepatomegaly. 5. Nonalcoholic patients

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Fatty liver Grade III 3. Positive Hepatitis markers 4. Patients suffering from systemic and metabolic diseases

Design outcomes

Primary

Measure	Time frame
Reduction in grade of Fatty Liver as per UltrasonogramTimepoint: before treatment and After treatment	—

Secondary

Measure	Time frame
Improvement in Quality of life.Timepoint: Before treatment and After treatment	—

Countries

India

Contacts

Public ContactDr Muzaffar Din Ahmad Bhat

National Institute of Unani Medicine

drmuzaffar79@gmail.com8618643497

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026